New drug duo aims to slow muscle decline in rare disease

NCT ID NCT06479863

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether a combination of two drugs, pozelimab and cemdisiran, can improve physical function in people with sporadic inclusion body myositis (sIBM), a rare muscle disease that causes progressive weakness. Ten adults aged 45 to 75 with sIBM will receive the treatment and be monitored for changes in muscle strength and daily activities. The goal is to see if the therapy can help control the disease and ease symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy inclusion body myositis myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Neuromuscular Center

    RECRUITING

    Austin, Texas, 78759, United States

  • Austin Neuromuscular Center

    RECRUITING

    Austin, Texas, 78759, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact